Earnings Summary

Sarepta Therapeutics, Inc.’s revenue jumped 20.24% since last year same period to $253.5Mn in the Q1 2023. On a quarterly growth basis, Sarepta Therapeutics, Inc. has generated -1.91% fall in its revenue since last 3-months.

Sarepta Therapeutics, Inc.’s net profit fell -392.03% since last year same period to $-516.76Mn in the Q1 2023. On a quarterly growth basis, Sarepta Therapeutics, Inc. has generated -373.03% fall in its net profits since last 3-months.

Sarepta Therapeutics, Inc.’s net profit margin fell -309.21% since last year same period to -203.85% in the Q1 2023. On a quarterly growth basis, Sarepta Therapeutics, Inc. has generated -382.22% fall in its net profit margins since last 3-months.

Sarepta Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.4 - a 2.1% jump from last quarter’s estimates.

Sarepta Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -1.4.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Sarepta Therapeutics, Inc.’s return on assets (ROA) stands at -0.12.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Sarepta Therapeutics, Inc.’s return on equity (ROE) stands at -1.42.